Key result
ASTIN demonstrates the feasibility of Bayesian adaptive design for real-time stroke dosing trials.
Answers are grounded in this paper and cite their sources.
The Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN) study, initiated in November of the year 2000, is now widely recognized as having been a landmark study in the history of clinical trials. We look at why this is the case by considering its key features and impact. These key features are: the use of Bayesian design and analysis; the use of the normal dynamic linear model; the response adaptive nature of the study; the use of real-time dosing decisions; and the use of an integrated model to predict 90-day response on the Scandinavian Stroke Scale. Our overall conclusion is that the ASTIN study's main impact came from showing the clinical trial community the feasibility of the novel design and analysis used when most of these key features were rarely used in industry trials, let alone used together in one trial in a disease area with a tremendous unmet medical need.
No takes yet. Share an insight, caveat, or question.
Kirby et al. (2022) conducted a review in Acute stroke. Bayesian adaptive clinical trial design was evaluated on 90-day response on the Scandinavian Stroke Scale. The ASTIN study demonstrated the feasibility of novel Bayesian adaptive trial designs and real-time dosing decisions for evaluating acute stroke therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: